A correct approach is necessary in patients with hyperkalemia . Read more.

If possible, in hyperkalemia in a patient with HFrEF , the RAAS blockers ( spironolactone , ACE inhibitors, ARB or ARNI) are not reduced or stopped if there is no hypotension and if renal function remains acceptable (with GFR > 20-30 ml/min ). More and more people are opting to associate a peroral potassium binder and continue RAAS blockers to maintain the beneficial effects of this heart failure therapy for as long as possible. These peroral potassium binders bind the potassium from food in the intestine, so that it is no longer absorbed into the body, but is excreted with the stool. There are currently 3 peroral potassium binders available, 2 of which are reimbursed specifically for heart failure: sodium zirconium cyclosilicate ( Lokelma ) and patiromer ( Veltassa ) .